HC Wainwright & Co. Reiterates Buy on Aldeyra Therapeutics, Maintains $15 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates Aldeyra Therapeutics (NASDAQ:ALDX) with a Buy and maintains $15 price target.
Earnings Scheduled For March 9, 2023
Companies Reporting Before The Bell
• Aurora Mobile (NASDAQ:JG) is expected to report earnings for its fourth quarter.
Earnings Outlook For Aldeyra Therapeutics
Aldeyra Therapeutics (NASDAQ:ALDX) is set to give its latest quarterly earnings report on Thursday, 2023-03-09. Here’s what investors…
Aldeyra Therapeutics’ RASP Modulator Shows Improved Signs of Alcohol Intoxication
Aldeyra Therapeutics Inc (NASDAQ:ALDX) announced a demonstration of target engagement and improvement in the signs of alcohol intoxication in the Phase…
Aldeyra Therapeutics’ Investigational RASP Modulator ADX-629 Improved Signs Of Intoxication In Alcohol Challenge Phase 2 Clinical Trial
Relative to Placebo, ADX-629 Reduced Dermal Flushing (P=0.0007), Increased Romberg Test Balance Time (P=0.02), and Lowered Levels of Acetaldehyde (P=0.03) Following Exposure to Alcohol
Aldeyra Plans to Support
Aldeyra Therapeutics Announces Primary Vitreoretinal Lymphoma Pre-NDA Meeting With FDA; Company Intends To Request Priority Review Designation
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced that, following the recent receipt of official minutes from its pre-NDA (New Drug Application) meeting with the U.S. Food and Drug Administration
Aldeyra’s ADX-2191 Aces Late-Stage Study In Rare Vision Disorder
Aldeyra Therapeutics Inc (NASDAQ:ALDX) achieved the primary endpoint in Part 1 of the Phase 3 GUARD Trial of ADX-2191 (methotrexate injection,…
Aldeyra Therapeutics Schedules Conference Call And Webcast To Announce Top-Line Results From Part 1 Of The Phase 3 GUARD Trial Of ADX-2191 In Proliferative Vitreoretinopathy October 6
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced it will host a webcast and conference call on Thursday, October 6, 2022, at 8:00 a.m. (ET) to report top-line results from Part 1 of the Phase 3
Important Biotech Catalysts For September 14, 2022 – End Of The Day Summary
The U.S. Food and Drug Administration (FDA) has granted fast track designation for the development of TRACON’s (NASDAQ:TCON)…
Earnings Scheduled For August 5, 2022
Companies Reporting Before The Bell
• Reservoir Media (NASDAQ:RSVR) is projected to report quarterly loss at $0.05 per share on revenue of $18.19 million.